Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

Oblimersen sodium (Genasense™) is an antisense oligodeoxynucleotide specific for the antiapoptotic protein Bcl-2, which could enhance the sensitivity of leukemic cells to chemotherapy in this ...

We have observed substantial anti–tumor activity against a range of tumor types in xenograft models after administration of the C–raf antisense. However, the doses required to achieve anti ...

Begin your TipRanks Premium journey today. Percheron Therapeutics (PERCF) Company Description: Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals.

Researchers from Splisense Ltd. and affiliated organizations recently reported preclinical data for SPL-84, an inhaled antisense oligonucleotide drug candidate being developed for the treatment of ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

Ionis' innovative antisense and siRNA technologies target RNA to treat various diseases, with potential multi-billion dollar peak revenue drugs nearing commercial approval. Despite modest 2024 ...

AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...